Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALRN-6924 + Paclitaxel in WT TP53 Advanced Solid Tumors
NCT03725436Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2019
- Primary completion
- Mar 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sulanemadlin in solid tumor (advanced stage), metastatic solid tumor and breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2019; status: completed.
02
Drugs
sulanemadlin
03
Conditions
solid tumor (advanced stage)metastatic solid tumorbreast cancer
Beyond the preview
Go deeper on NCT03725436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725436.